Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03517488 · ClinicalTrials.gov registry record · Phase 1
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
A Phase 1 study of Melanoma and Hepatocellular Carcinoma, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 17
- Study locations
NCT03517488: Completed Phase 1 study of Melanoma and Hepatocellular Carcinoma, sponsored by Xencor.
NCT03517488 is a Phase 1 study of Melanoma and Hepatocellular Carcinoma that has completed, run by Xencor. The registered enrollment target is 150 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (79% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03517488, a Phase 1 study of Melanoma and Hepatocellular Carcinoma, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
Primary Outcome
Treatment-related adverse events as assessed by CTCAE v4.03
Conditions Studied
Interventions
- BIOLOGICAL XmAb20717
Study Locations (17)
California
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- UCLA Hematology-Oncology Clinic (Westwood) - Los Angeles
- University of California San Diego Moores Cancer Center - San Diego
- University of California San Francisco Medical Center - San Francisco
New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone - New York
- Columbia University Medical Center - Herbert Irving Pavilion - New York
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago Medicine - Chicago
Kansas
- The University of Kansas Clinical Research Center - Fairway
Michigan
- Karmanos Cancer Institute - Detroit
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-07-10 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 1 |
What the finished NCT03517488 record still lists
NCT03517488 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (79% lower).
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which XmAb20717 is the first listed.
NCT03517488 lists 17 locations in 12 states (California, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT03517488 about?
NCT03517488 is a clinical study titled "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors". This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
What is the current status of trial NCT03517488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2018-07-10. Estimated completion is 2022-09-06.
What conditions does trial NCT03517488 study?
This clinical trial studies the following conditions: Melanoma, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Carcinoma, Urothelial Carcinoma.
What interventions are being tested in trial NCT03517488?
The interventions under investigation include: XmAb20717 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03517488?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03517488 being conducted?
This trial has 17 study locations across California, Georgia, Illinois, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03517488's enrollment target sits among peer trials
150 88th of 266 higher than 179 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI